Hepatitis B immunization in a low-incidence province of canada: Comparing alternative strategies

Medical Decision Making

Volumn 17, Issue 4, 1997, Pages 472-482

  Wiebe, Tim ^b   Fergusson, Patricia ^a   Horne, Digby ^b   Shanahan, Marian ^b   Macdonald, Anna ^b   Heise, Lynn ^b   Roos, Leslie L ^b  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b NONE

Author keywords

Cost effectiveness; Hepatitis B; Immunization

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INCIDENCE; SCHOOL CHILD;

CARCINOMA, HEPATOCELLULAR; CHILD; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; FEMALE; HEPATITIS B; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; INTERFERONS; LIVER CIRRHOSIS; MANITOBA; MARKOV CHAINS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 0030818095     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9701700413     Document Type: Article

References (50)

1. Last JM, Wallace RB. Public Health and Preventive Medicine, 13th ed. Norwalk, CT: Appleton and Lange, 1992.
2. Evans AS (ed). Viral Infections of Humans: Epidemiology and Control. 3rd ed. New York: Plenum, 1989.
3. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis. 1992;14:697-707.
4. Report of the Working Group on the Possible Relationship between Hepatitis B Vaccination and the Chronic Fatique Syndrome. Canada Communicable Disease Report. February 1993;19(4).
5. Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost - effectiveness. Vaccine. August 1988;6:299-303.
6. Alter MJ, Hadler SC, Margolis HS. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA. 1990;263:1218-22.
7. Report of the Hepatitis B Working Group. Canada Communicable Disease Report. 1994;20(13):105-12.
8. Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR. 1991;40:RR-13:1-25.
9. Committee on Infectious Diseases. Universal hepatitis B immunization. Pediatrics. 1992;89:795-800.
10. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Hepatitis B in Canada: the case for universal vaccination. Can Med Assoc J. 1992;146:25-8.
11. Benenson AS (ed). Control of Communicable Diseases in Manitoba. American Public Health Association, 15th ed. Washington, DC: APHA, 1990.
12. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine based on cost - effectiveness analysis. N Engl J Med. 1982;307:644-52.
13. Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost - effectiveness analysis. Med Decis Making. 1993;13:4-20.
14. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost - effectiveness analysis. Ann Intern Med. 1993;118:298-306.
15. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. JAMA. 1995;274:1201-8.
16. Rossi PH, Freeman HE. Evaluation: A Systematic Approach, Newbury Park, CA: Sage, 1989.
17. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost - effectiveness. Risk Anal. 1995;15:369-90.
18. Drummond MF, Stoddard GL. Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press, 1987.
19. SMLTREE Version 2.9, copyright Jim Hollenberg, 1989.
20. Lo KJ, Lee SD, Tsai YT, et al. Long term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg positive HBsAg carrier mothers. Hepatology. 1988;8:1647-50.
21. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effects of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993;119:312-23.
22. Shanahan M. Update to hospital case-mix costing project 1993/94. Manitoba Centre for Health Policy and Evaluation. Unpublished. March 1996.
23. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-81.
24. Minuk G, Hepatologist, Liver Unit, Health Sciences Centre, Winnipeg, Manitoba, Personal communication, 1996.
25. Roberts JD, Poffenroth LA, Roos LL, Bebchuk JD, Carter AO. Monitoring childhood immunizations: a Canadian Approach. Am J Public Health. 1994;84:1666-8.
26. American Academy of Pediatrics. Hepatitis B. In Peter G (ed). 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994;224.
27. Holton D. Revised guidelines for booster vaccination against hepatitis B. Can Med Assoc J. 1192;147:1029-32.
28. King GE, Hatller SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis. J. 1994;13:394-407.
29. Roberts JD, Roos LL, Poffenroth LA, et al. Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. J Clin Epidemiol. 1996;49:51-8.
30. Manitoba Health, 1995.
31. Sekla LH, Hammond G, Stackiw W, Elibisch G, Fast M. Testing pregnant women for HBsAg: a pilot study in Manitoba. Can Dis Weekly Rep. 1988;14(31):137-40.
32. Statistics Canada. Deaths. Vital Statistics, Vol. 3. Hull, Quebec: Ministry of Supply and Services, Canada, 1988: Cat. 84-206.
33. Coursaget P, Yvonnet B, Chotard J, et al. Age and sex related study of hepatitis B virus chronic carrier state in infants from an endemic area. J Med Virol. 1987;22:1-5.
34. Nielson JO, Dietrichson O, Elling P, Christofferson P. Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med. 1971;285:1157-60.
35. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B related sequelae. Prospective study in 1,400 hepatitis B surface antigen positive Alaska native carriers. Arch Intern Med. 1990;150:1051-4.
36. Alward W, McMahon B, Hall D, Heyward WL, Francis DP, Bender TR. The long term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis. 1985;151:604-9.
37. Sampliner RE, Hamilton F, Iseri O, Tabor F, Boitnott J. The liver histology and frequency of clearance of hepatitis B surface antigen in chronic carriers. Am J Med Sci. 1979;277:17-22.
38. Wong WWS, Minuk GY. A cross-sectional seroepidomiologic survey of chronic hepatitis B virus infections in Southeast Asian immigrants residing in a Canadian urban center. Clin Invest Med. 1994; Vol. 17:443-7.
39. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493-6.
40. Lo KJ, Tong MJ, Chien MC, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis. 1982;146:205-10.
41. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols J. Survival in chronic hepatitis B. Ann Intern Med. 1984;101:613-6.
42. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis R after alpha-interferon therapy. Ann Intern Med. 1991;114:629-34.
43. Beasley RP, Hwang LY, Lin CC, Chein CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-33.
44. Silverberg E, Lubera J. Cancer Statistics. CA-A Cancer Journal for Clinicians. 1989;39(1):3-20.
45. McMahon BJ, Alward W, Hall D, et al. Acute hepatitis B infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
46. Hadler SC, Judson FN, O'Malley PM. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991;163:454-9.
47. Scott R, Schneider RJ, Snitbhan, Karwacki JJ Jr. Factors relating to transmission of viral hepatitis in a United States military population stationed in Thailand. Am J Epidemiol. 1981;113:520-8.
48. Rinker J, Galambos JT. Prospective study of hepatitis B in thirty-two inadvertently infected people. Gastroenterology. 1981;81:686-91.
49. Beasley RP, Hwang L, Lin C, Ko V, Two S. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol. 1983;117:213-22.
50. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1:377-85.